ATE530193T1 - Verfahren zur steigerung der klasse i präsentation von exogenen antigene durch humane dendritische zellen - Google Patents

Verfahren zur steigerung der klasse i präsentation von exogenen antigene durch humane dendritische zellen

Info

Publication number
ATE530193T1
ATE530193T1 AT01933328T AT01933328T ATE530193T1 AT E530193 T1 ATE530193 T1 AT E530193T1 AT 01933328 T AT01933328 T AT 01933328T AT 01933328 T AT01933328 T AT 01933328T AT E530193 T1 ATE530193 T1 AT E530193T1
Authority
AT
Austria
Prior art keywords
dendritic cells
presentation
processing
class
population
Prior art date
Application number
AT01933328T
Other languages
English (en)
Inventor
Michael Salgaller
Alton Boynton
Original Assignee
Northwest Biotherapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Northwest Biotherapeutics Inc filed Critical Northwest Biotherapeutics Inc
Application granted granted Critical
Publication of ATE530193T1 publication Critical patent/ATE530193T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001193—Prostate associated antigens e.g. Prostate stem cell antigen [PSCA]; Prostate carcinoma tumor antigen [PCTA]; PAP or PSGR
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001193—Prostate associated antigens e.g. Prostate stem cell antigen [PSCA]; Prostate carcinoma tumor antigen [PCTA]; PAP or PSGR
    • A61K39/001194—Prostate specific antigen [PSA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001193—Prostate associated antigens e.g. Prostate stem cell antigen [PSCA]; Prostate carcinoma tumor antigen [PCTA]; PAP or PSGR
    • A61K39/001195—Prostate specific membrane antigen [PSMA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/461—Cellular immunotherapy characterised by the cell type used
    • A61K39/4615—Dendritic cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/462—Cellular immunotherapy characterized by the effect or the function of the cells
    • A61K39/4622—Antigen presenting cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/4644—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/4644—Cancer antigens
    • A61K39/464402—Receptors, cell surface antigens or cell surface determinants
    • A61K39/464411—Immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/4644—Cancer antigens
    • A61K39/464493—Prostate associated antigens e.g. Prostate stem cell antigen [PSCA]; Prostate carcinoma tumor antigen [PCTA]; Prostatic acid phosphatase [PAP]; Prostate-specific G-protein-coupled receptor [PSGR]
    • A61K39/464495—Prostate specific membrane antigen [PSMA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/4644—Cancer antigens
    • A61K39/464499—Undefined tumor antigens, e.g. tumor lysate or antigens targeted by cells isolated from tumor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4648—Bacterial antigens
    • A61K39/464819—Bacillus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/464838—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5154—Antigen presenting cells [APCs], e.g. dendritic cells or macrophages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5158—Antigen-pulsed cells, e.g. T-cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/26—Universal/off- the- shelf cellular immunotherapy; Allogenic cells or means to avoid rejection

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Cell Biology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Developmental Biology & Embryology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Urology & Nephrology (AREA)
  • Virology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
AT01933328T 2000-05-12 2001-05-11 Verfahren zur steigerung der klasse i präsentation von exogenen antigene durch humane dendritische zellen ATE530193T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US20375800P 2000-05-12 2000-05-12
PCT/US2001/015428 WO2001087325A1 (en) 2000-05-12 2001-05-11 Method to increase class i presentation of exogenous antigens by human dendritic cells

Publications (1)

Publication Number Publication Date
ATE530193T1 true ATE530193T1 (de) 2011-11-15

Family

ID=22755184

Family Applications (1)

Application Number Title Priority Date Filing Date
AT01933328T ATE530193T1 (de) 2000-05-12 2001-05-11 Verfahren zur steigerung der klasse i präsentation von exogenen antigene durch humane dendritische zellen

Country Status (12)

Country Link
US (2) US20030175247A1 (de)
EP (2) EP1292321B1 (de)
JP (4) JP4841794B2 (de)
AT (1) ATE530193T1 (de)
AU (3) AU2001259760B2 (de)
CA (1) CA2407104A1 (de)
DK (2) DK1292321T3 (de)
ES (2) ES2375948T3 (de)
HK (1) HK1161977A1 (de)
IL (4) IL152655A0 (de)
NZ (1) NZ522807A (de)
WO (1) WO2001087325A1 (de)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030175247A1 (en) * 2000-05-12 2003-09-18 Michael Salgaller Method to increase class I presentation of exogenous antigens by human dendritic cells
AU2013201707B2 (en) * 2001-09-06 2017-04-27 Northwest Biotherapeutics, Inc. Compositions and methods for priming monocytic dendritic cells and T cells for Th-1 response
BRPI0212545B8 (pt) * 2001-09-06 2021-05-25 Northwest Biotherapeutics Inc método ex vivo ou in vitro para produzir uma população de célula dendrítica madura e método para produzir células t
US20050215472A1 (en) 2001-10-23 2005-09-29 Psma Development Company, Llc PSMA formulations and uses thereof
EP2363404B8 (de) 2001-10-23 2016-12-07 PSMA Development Company L.L.C. PSMA Antikörper
CA2468258C (en) * 2001-11-30 2011-10-11 Jeffrey Schlom Peptide agonists of prostate-specific antigen, and uses therefor
JP4624377B2 (ja) * 2001-12-10 2011-02-02 株式会社グリーンペプタイド 腫瘍抗原
EP1462456A4 (de) * 2001-12-10 2005-09-21 Greenpeptide Co Ltd Tumorantigene
WO2009127046A1 (en) * 2008-04-14 2009-10-22 Proscan Rx Pharma Inc. Prostate specific membrane antigen antibodies and antigen binding fragments
US8728465B2 (en) 2008-06-17 2014-05-20 Cedars-Sinai Medical Center Use of toll-like receptor ligands as adjuvants to vaccination therapy for brain tumors
PL2326350T3 (pl) 2008-09-08 2014-03-31 Psma Dev Company L L C Związki do zabijania eksprymujących PSMA, opornych na taksan komórek rakowych
US8728806B2 (en) 2008-12-06 2014-05-20 The Board Of Regents, The University Of Texas System Methods and compositions related to Th-1 dendritic cells
US8858952B2 (en) 2009-02-19 2014-10-14 Mayo Foundation For Medical Education And Research Methods and materials for generating T cells
WO2011084479A1 (en) * 2009-12-15 2011-07-14 Immuneregen Biosciences, Inc. Substance p and analogs thereof as adjuvant therapy for adoptive cellular immunotherapy
RU2530523C2 (ru) * 2012-03-29 2014-10-10 Олег Борисович Егоров Способ противоопухолевой иммунотерапии
KR101985769B1 (ko) 2013-03-15 2019-06-04 동우 화인켐 주식회사 마스크리스 디지털 노광 방식을 통한 컬러 필터의 제조 방법
GB201315321D0 (en) * 2013-08-28 2013-10-09 Koninklijke Nederlandse Akademie Van Wetenschappen Transduction Buffer
EP3104878B1 (de) * 2014-02-14 2019-05-22 Immune Design Corp. Immuntherapie von krebs durch kombination von lokaler und systemischer immunstimulation
DE102015106810A1 (de) 2015-04-30 2016-11-03 Infineon Technologies Ag Implantierbare Vorrichtung und implantierbares System mit dieser
CN114246942A (zh) * 2020-09-24 2022-03-29 刘慧宁 肿瘤复合抗原、树突状细胞多价疫苗及其应用

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3753357A (en) 1970-12-14 1973-08-21 Ovitron Res Corp Method and apparatus for the preservation of cells and tissues
US4199022A (en) 1978-12-08 1980-04-22 The United States Of America As Represented By The Department Of Energy Method of freezing living cells and tissues with improved subsequent survival
US4559298A (en) 1982-11-23 1985-12-17 American National Red Cross Cryopreservation of biological materials in a non-frozen or vitreous state
US5162504A (en) 1988-06-03 1992-11-10 Cytogen Corporation Monoclonal antibodies to a new antigenic marker in epithelial prostatic cells and serum of prostatic cancer patients
AU650045B2 (en) 1990-09-12 1994-06-09 Lifecell Corporation Method and apparatus for cryopreparation dry stabilization and rehydration of biological suspensions
US5227471A (en) 1992-01-30 1993-07-13 Eastern Virginia Medical School Of The Medical College Of Hampton Roads Monoclonal antibody PD41 that binds to a prostate mucin antigen that is expressed in human prostatic carcinoma
JP3649335B2 (ja) * 1992-04-01 2005-05-18 ザ ロックフェラー ユニバーシティー 樹枝状細胞前駆体のインビトロ増殖の方法およびその免疫原製造への使用
AU4678993A (en) 1992-07-16 1994-02-14 Board Of Trustees Of The Leland Stanford Junior University Methods for using dendritic cells to activate t cells
NZ263050A (en) * 1993-03-05 1997-11-24 Cytel Corp Compositions of immunogenic peptides with hla-a2.1 binding motifs
US5788963A (en) * 1995-07-31 1998-08-04 Pacific Northwest Cancer Foundation Isolation and/or preservation of dendritic cells for prostate cancer immunotherapy
US6130087A (en) 1996-10-07 2000-10-10 Fordham University Methods for generating cytotoxic T cells in vitro
IL125608A0 (en) * 1998-07-30 1999-03-12 Yeda Res & Dev Tumor associated antigen peptides and use of same as anti-tumor vaccines
CA2370413A1 (en) * 1999-06-29 2001-01-04 Epimmune Inc. Hla binding peptides and their uses
US20030175247A1 (en) * 2000-05-12 2003-09-18 Michael Salgaller Method to increase class I presentation of exogenous antigens by human dendritic cells

Also Published As

Publication number Publication date
EP2363139B1 (de) 2016-03-02
NZ522807A (en) 2004-11-26
ES2571979T3 (es) 2016-05-27
IL152655A0 (en) 2003-06-24
EP1292321A1 (de) 2003-03-19
IL152655A (en) 2014-03-31
JP2015108018A (ja) 2015-06-11
EP2363139A1 (de) 2011-09-07
HK1161977A1 (zh) 2012-08-17
AU2001259760B2 (en) 2006-10-05
JP2011225628A (ja) 2011-11-10
CA2407104A1 (en) 2001-11-22
JP2003533486A (ja) 2003-11-11
WO2001087325A1 (en) 2001-11-22
EP1292321A4 (de) 2005-09-21
EP1292321B1 (de) 2011-10-26
US20030175247A1 (en) 2003-09-18
DK1292321T3 (da) 2012-01-30
ES2375948T3 (es) 2012-03-07
JP2014001244A (ja) 2014-01-09
IL231081A0 (en) 2014-03-31
JP4841794B2 (ja) 2011-12-21
AU2007200049A1 (en) 2007-01-25
IL248493A0 (en) 2016-11-30
AU5976001A (en) 2001-11-26
IL231081A (en) 2016-11-30
US20080171023A1 (en) 2008-07-17
DK2363139T3 (en) 2016-05-30

Similar Documents

Publication Publication Date Title
IL248493A0 (en) A method for increasing type 1 presentation of exogenous antigens using dendritic cells of human origin
Zhou et al. CD14+ blood monocytes can differentiate into functionally mature CD83+ dendritic cells.
Hunter et al. Histochemical demonstration of enzymes separated by zone electrophoresis in starch gels
Blank et al. Parasitism of epidermal Langerhans cells in experimental cutaneous leishmaniasis with Leishmania major
CN1172718C (zh) 树突状细胞刺激因子
Tuschl et al. The expression of surface markers on dendritic cells as indicators for the sensitizing potential of chemicals
KR101527260B1 (ko) 수상세포의 제조방법
WO2006065495A3 (en) Methods of using il-21 for adoptive immunotherapy and identification of tumor antigens
BRPI0212545A8 (pt) método ex vivo ou in vitro para produzir uma população de célula dendrítica madura e método para produzir células t
ATE411380T1 (de) Verfahren zur herstellung gebrauchsfertiger, antigenbeladener oder -unbeladener, kryokonservierter, reifer dendritischer zellen
CA2368855A1 (en) Differentiation of monocytes into functional dendritic cells
ATE495238T1 (de) Iin vitro methode um eine potentielle reaktion eines tieres an einen agenten zu bestimmen
JP2005532803A5 (de)
KR20180137488A (ko) 간엽 마커와 뉴런 마커를 발현하는 줄기 세포, 이의 조성물 및 이의 제조 방법
CN105007930B (zh) 用于治疗疾病的同种异体自噬体富集组合物
Rustemeyer et al. Human T lymphocyte priming in vitro by haptenated autologous dendritic cells
MX2022004186A (es) Composiciones y métodos in vitro para potenciar la activación de células dendríticas y células t, y para inducir una respuesta inmune th-1.
Coutant et al. Early changes in murine epidermal cell phenotype by contact sensitizers.
Magee et al. Methods of harvesting mammalian cells grown in tissue culture.
CN105132386A (zh) 一种外分泌体及其制备方法和其作为肿瘤疫苗的应用
JP2015509382A (ja) 組織構築体およびその使用
JP2004520033A (ja) 分化拘束された成熟樹状細胞の調製用補助組成物
Vremec et al. The purification of large numbers of antigen presenting dendritic cells from mouse spleen
Sjaastad et al. Reduced T Cell Priming in Microbially Experienced “Dirty” Mice Results from Limited IL-27 Production by XCR1+ Dendritic Cells
Tawara et al. Host basophils are dispensable for induction of donor T helper 2 cell differentiation and severity of experimental graft-versus-host disease